medigraphic.com
ISSN 0188-2198 (Print)

2007, Number 3

<< Back

Rev Mex Cardiol 2007; 18 (3)

The clinical studies based in hard points and statistics. New paradigm; to believe or not believe, that is the question: Second part

Luque CAF, Eguia BA

Language: Spanish
References: 13
Page: 136-141
PDF size: 96.63 Kb.


ABSTRACT

In this second part we will analyzed the structure of a clinical randomized trial, its methodology and other important aspects that can influenced interpretation and analysis and how to apply in clinical practice.


REFERENCES

  1. The European Agency for Evaluation of Medicinal Products. Statistical Principles for Clinical trials. http://www.emea.eu.int/pdfs/human/ich/036396en.pdf

  2. Abraira V. Medidas del efecto de un tratamiento (I): Reducción absoluta del riesgo reducción relativa y riesgo relativo SEMERGEN. 2000; 26: 535-536.

  3. Luque CAF, Balderrama AE. Carta al editor. Rev Mex Cardiol 2003; 14 (3): 98-102.

  4. Abraira V. Medidas del efecto de un tratamiento (II): odds ratio y número necesario para tratar SEMERGEN. 2001; 27: 418-420.

  5. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part I. Circulation 2002; 106: 1015-1021.

  6. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part II. Circulation 2002; 106: 1172-1175.

  7. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

  8. Peterson J, Lauer MS. Cleveland. Clin J Med 2001; 68: 569-574.

  9. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581–588.

  10. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.

  11. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.

  12. Lexchin J, Bero LA, Djulbegovic B et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170.

  13. Dahlöf B, Sever PS, Poulter NR for the ASCOT investigators Prevention of Cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.




2020     |     www.medigraphic.com